72067423RFA00002: Achieving and Sustaining HIV/TB Epidemic Control in the Eastern Cape Province – Integrated Service Delivery Response
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of South Africa USAID-Pretoria notices from 2022.
South Africa USAID-Pretoria offered grants of up to $75.0 million (at least $75.0 million) to the applicants described in the notice. It expected to make one award. Applications closed on January 4, 2023.
From the official notice on Grants.gov, last changed October 17, 2022. Checked November 7, 2026.
- Award ceiling$75.0 million
- Award floor$75.0 million
- Expected awards1
- Cost sharingRequired
- Funding typeCooperative Agreement
Key dates
| Posted | October 17, 2022 |
|---|---|
| Deadline | January 4, 2023 |
| Archived by Grants.gov | February 3, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility under this Notice of Funding Opportunity (NOFO) is restricted to local entities.(1) Is legally organized under the laws of South Africa; (2) Has as its principal place of business or operations in South Africa; (3) Is majority owned by individuals who are citizens or lawful permanent residents of South Africa; and (4) Is managed by a governing body the majority of who are citizens or lawful permanent residents of the country receiving assistance.
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $75.0 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- The notice requires cost sharing or matching funds, so you must contribute part of the project cost.
What the grant funds
The goal of USAID’s “Achieving and Sustaining HIV Epidemic Control in the Eastern Cape Province - Integrated Service Delivery Response” (hereinafter referred to as the Activity) is to support long, healthy lives for the population of the Eastern Cape Province by achieving and sustaining HIV/TB epidemic control. USAID aims to reach this goal by achieving the following strategic objectives: (1) Close the gaps to HIV epidemic control; (2) Sustain health gains through strengthened, improved, and resilient health systems; and (3) Leverage community, civil society and private sector partnerships to improve and sustain service delivery and client outcomes. The Activity emphasizes a continuum of care approach across health facilities, communities and households, particularly for services targeting orphans and other children vulnerable to HIV (OVC). USAID intends to implement the Activity in the following five high HIV/TB burden districts in the Eastern Cape: 1) Buffalo City Metro, 2) Alfred Nzo District, 3) Amathole District, 4) Chris Hani District, and 5) Oliver Tambo District. USAID may change the geographic coverage based on epidemiological data and/or Government of South Africa (GoSA) and U.S. Government (USG) priorities. The estimated period of performance of the Activity is five years, and the total estimated amount to be awarded is approximately US$75 million.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 72067423RFA00002 still open?
No. It closed on January 4, 2023.
Who can apply for Achieving and Sustaining HIV/TB Epidemic Control in the Eastern Cape Province – Integrated Service Delivery Response?
South Africa USAID-Pretoria accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Achieving and Sustaining HIV/TB Epidemic Control in the Eastern Cape Province – Integrated Service Delivery Response?
Closed January 4, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $75.0 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)